Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...

Moderna stock (MRNA) fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US ...

Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and COVID-19 cases in the U.S. following the latest ...

Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...

Vaccine makers' stocks surged on Tuesday after the US reported its first bird flu death. Moderna, Novavax, and CureVac saw double-digit gains, while Pfizer and GSK also rose. The drugmakers have ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...

Meta Platforms is ending fact-checking and speech restrictions across Facebook and Instagram, as Chief Executive Mark Zuckerberg embraces a second Trump presidency. Starting in the U.S., Meta will ...

Moderna is still generating decent sales from its COVID-19 vaccine. The biotech has won important clinical and regulatory approvals this year. Moderna's portfolio should look much stronger in a ...